Stock Futures – Weekly CEO Buys Spotlight
– By Pleasure Hu
In keeping with GuruFocus Insider Information, these had been the most important CEO buys through the previous week.
Summit Therapeutics Inc. (NASDAQ:SMMT) CEO and 10% Proprietor Robert W. Duggan purchased 14,071,856 shares on Nov. 6 at a price of $3.34. The price of the stock has elevated by 45.21% since then.
Summit Therapeutics is a biopharmaceutical firm. It’s concerned within the enterprise of discovery, growth and commercialization of medicines for indications for which there are insufficient or no therapies. All belongings of the corporate are positioned in the UK.
The corporate has a market cap of $1.63 billion. Its shares traded at $4.85 as of Nov. 13.
Web loss for the quarter ended June 30 was $15.23 million in comparison with a lack of $6.68 million for the prior-year interval.
American Property Belief
American Property Belief Inc. (NYSE:AAT) Chairman, CEO, President and 10% Proprietor Ernest S. Rady purchased 184,994 shares through the previous week on the common price of $22.75.
American Property Belief is a self-administered actual property funding belief based mostly in america. The corporate invests in, operates and develops retail, workplace, residential and mixed-use properties primarily positioned in California, Oregon, Washington and Hawaii.
The corporate has a market cap of $1.60 billion. Its shares traded at $26.60 with a price-earnings ratio of 42.29 as of Nov. 13.
Web earnings for the third quarter of 2020 was $5.zero million in comparison with $12.9 million for the third quarter of 2019.
Rady purchased 175,739 shares on Nov. Four at a price of $21.64; 130,000 shares on Nov. 6 at a price of $21.49; and 54,994 shares on Nov. 11 on the common price of $25.72. Since then, the price of the stock has elevated by 3.42%.
Dun & Bradstreet Holdings
Dun & Bradstreet Holdings Inc. (NYSE:DNB) CEO Anthony M. Jabbour purchased 38,000 shares on Nov. 6 at a price of $26.31. The price of the stock has elevated by 4.14% since then.
Dun & Bradstreet Holdings is among the main suppliers of enterprise decisioning information and analytics. The corporate supplies business credit score decisioning, which helps companies to make knowledgeable selections when contemplating extending enterprise loans and commerce credit score. Additionally, the corporate presents options to corporations seeking to analyze provider relationships and extra successfully gather excellent receivables. Different companies embrace digital advertising, gross sales acceleration and danger administration, amongst others.
The corporate has a market cap of $11.59 billion. Its shares traded at $27.40 as of Nov. 13.
On June 30, the corporate introduced the pricing of its preliminary public providing of 78,302,272 shares of widespread stock at an preliminary public providing price of $22.00 per share.
Chief Monetary Officer Bryan T. Hipsher purchased 4,000 shares on Nov. 6 at a price of $26.39. Since then, the price of the stock has elevated by 3.83%.
OPKO Well being
OPKO Well being Inc. (NASDAQ:OPK) CEO, Chairman and 10% Proprietor Phillip Frost purchased 250,000 shares on Nov. 9 at a price of $3.18. The price of the stock has elevated by 25.47% since then.
Opko Well being is a diversified biotechnology firm that operates pharmaceutical and diagnostic growth applications. Opko’s diagnostics enterprise features a core genetic testing operation. It has a growth and business provide pharmaceutical firm, in addition to a worldwide supply-chain operation and holding firm in Eire. Opko additionally owns a specialty energetic pharmaceutical components producer in Israel.
The corporate has a market cap of $2.67 billion. Its shares traded at $3.99 as of Nov. 13.
Web earnings for the third quarter of 2020 was $23.7 million in contrast with a internet lack of $62.zero million for the comparable interval of 2019.
Frost additionally purchased 600,000 shares on Oct. 30 at a price of $3.45. Since then, the price of the stock has elevated by 15.65%.
ViewRay Inc. (NASDAQ:VRAY) President and CEO Scott William Drake purchased 155,000 shares on Nov. 10 at a price of $3.23. The price of the stock has elevated by 20.74% since then.
ViewRay is a radiation remedy and imaging expertise firm. It designs, manufactures and markets radiation remedy programs that present real-time imaging throughout radiation therapy. Its product portfolio encompasses The MRIdian linac system, The MRIdian system, Monte Carlo therapy planning system, and many others. The corporate holds license for its mixture of MRI and radiation remedy applied sciences.
The corporate has a market cap of $579.15 million. Its shares traded at $3.90 as of Nov. 13.
Web loss for the third quarter of 2020 was $28.13 million in comparison with a lack of $20.83 million for the prior-year interval.
For the entire record of stocks purchased by their firm CEOs, go to: CEO Buys.
Disclosure: I don’t personal stock in any of the businesses talked about within the article.
Not a Premium Member of GuruFocus? Join a free 7-day trial right here.
This text first appeared on GuruFocus.
Stock Futures – Weekly CEO Buys Spotlight